<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03747328</url>
  </required_header>
  <id_info>
    <org_study_id>LS007</org_study_id>
    <nct_id>NCT03747328</nct_id>
  </id_info>
  <brief_title>ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome</brief_title>
  <official_title>A Phase 2a, Open-label Study to Evaluate the Safety, Tolerability, and Clinical Activity of ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aadi, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aadi, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2a, open-label study to evaluate the safety, tolerability, and clinical activity of&#xD;
      ABI-009 (nab-sirolimus) in patients with genetically-confirmed Leigh or Leigh-like syndrome&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2022</start_date>
  <completion_date type="Anticipated">March 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events in pediatric patients with genetically-confirmed Leigh or Leigh-like syndrome administered ABI-009 intravenously (IV)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Adverse events will be measured according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Leigh Syndrome</condition>
  <arm_group>
    <arm_group_label>ABI-009</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nanoparticle albumin bound sirolimus (ABI-009). Dose levels 1, 2.5, 5 and 10 mg/m2 given weekly for 8 cycles of ABI-009 (each cycle is weekly dosing for 2 weeks followed by a week of rest (qw2/3))</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-009</intervention_name>
    <description>nanoparticle albumin bound sirolimus</description>
    <arm_group_label>ABI-009</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A patient will be eligible for inclusion in this study only if all of the following&#xD;
        criteria are met at screening:&#xD;
&#xD;
          1. Diagnosis of genetically-confirmed Leigh or Leigh-like syndrome, as well as documented&#xD;
             clinical evidence (including demonstrated neurologic manifestations) of the syndrome,&#xD;
             as confirmed by the investigator.&#xD;
&#xD;
          2. Moderate disease severity based on NPMDS score of &gt;15 on Sections I through III,&#xD;
             inclusive.&#xD;
&#xD;
          3. Male or female patients, ≥2 and ≤17 years of age at the time of enrollment.&#xD;
&#xD;
          4. Body weight ≥5 kg (11 lbs) at the time of enrollment.&#xD;
&#xD;
          5. Chronic, stable disease, as determined by the investigator, for a minimum of 3 months&#xD;
             prior to enrollment. This includes, but is not limited to, patients without&#xD;
             hospitalizations or emergency room visits, or fever &lt;101 F, and/or acute illness.&#xD;
&#xD;
          6. Adequate liver function:&#xD;
&#xD;
               1. Total bilirubin ≤1.5 x upper limit of normal (ULN) mg/dL&#xD;
&#xD;
               2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt;3 x ULN.&#xD;
&#xD;
          7. Adequate renal function as defined by serum creatinine &lt;ULN for each individual&#xD;
             patient's age category.&#xD;
&#xD;
          8. Adequate biological parameters:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥1.5 × 109/L&#xD;
&#xD;
               2. Platelet count ≥100,000/mm3 (100 × 109/L)&#xD;
&#xD;
               3. Hemoglobin ≥9 g/dL.&#xD;
&#xD;
               4. Adequate immunoglobulin levels (IgG, IgA, IgM) that, in the opinion of the&#xD;
                  investigator, will not place the patient at increased risk for infection.&#xD;
&#xD;
               5. Serum amylase and lipase &lt;2 x ULN.&#xD;
&#xD;
               6. Non-fasting serum triglyceride ≤300 mg/dL and non-fasting serum cholesterol ≤300&#xD;
                  mg/dL, collected within 1 to 4 hours following a meal.&#xD;
&#xD;
          9. If receiving prescribed medication to prevent or treat seizures, the patient must be&#xD;
             receiving stable doses for at least 1 month prior to screening visit.&#xD;
&#xD;
         10. Sexually active males with female partners of child-bearing potential or non-pregnant&#xD;
             and non-breast feeding female of child-bearing potential:&#xD;
&#xD;
               -  Females of child-bearing potential must agree to use effective contraception&#xD;
                  without interruption from 28 days prior to starting IP throughout 3 months after&#xD;
                  last dose of IP and have a negative urine pregnancy test (β-hCG) result at&#xD;
                  screening and agree to ongoing pregnancy testing during the course of the study,&#xD;
                  and after the end of study treatment. A second form of birth control is required&#xD;
                  even if the patient has had a tubal ligation.&#xD;
&#xD;
               -  Male patients must practice abstinence or agree to use a condom during sexual&#xD;
                  contact with a pregnant female or a female of childbearing potential while&#xD;
                  participating in the study and throughout 3 months after the last dose of IP. A&#xD;
                  second form of birth control is required even if the patient has undergone a&#xD;
                  successful vasectomy.&#xD;
&#xD;
         11. The patient (when applicable) or the patient's parent(s) or legal guardian(s)&#xD;
             understand(s) and voluntarily signed the informed consent document(s) prior to any&#xD;
             study-related assessments/procedures being conducted.&#xD;
&#xD;
         12. The patient or parent(s)/guardian(s) is/are willing and able to comply with the study&#xD;
             visit schedule and other protocol requirements, in the opinion of the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A patient will not be eligible for inclusion in this study if any of the following criteria&#xD;
        apply at screening:&#xD;
&#xD;
          1. Renal insufficiency that, in the opinion of the investigator, requires or may require&#xD;
             dialysis during the treatment and follow-up periods.&#xD;
&#xD;
          2. Cardiac ejection fraction/shortening fraction ≤50 % and/or severe end-organ&#xD;
             hypo-perfusion syndrome (secondary to cardiac failure) resulting in lactic acidosis.&#xD;
&#xD;
          3. Patients with implanted cardiac assist/medical devices (including pacemakers), unless&#xD;
             device was implanted prophylactically, and the patient is clinically asymptomatic.&#xD;
&#xD;
          4. In the opinion of the investigator, clinically significant ECG and/or ECHO findings at&#xD;
             the time of screening.&#xD;
&#xD;
          5. Myocardial infarction within 6 months prior to enrollment.&#xD;
&#xD;
          6. Symptomatic congestive heart failure (CHF), unstable angina pectoris, cardiac&#xD;
             arrhythmia, uncontrolled hypertension, or unstable coronary artery disease.&#xD;
&#xD;
          7. Prior exposure to ABI-009, sirolimus, everolimus, or any other known rapamycin&#xD;
             derivative, or previous treatment with any known mTOR inhibitor.&#xD;
&#xD;
          8. Patients who are breast feeding or have a confirmed or suspected pregnancy.&#xD;
&#xD;
          9. Treatment with any investigational drug (ie, a drug for which there is no approved&#xD;
             indication), including an investigational drug for mitochondrial disease within 1&#xD;
             month prior to receiving the first dose of study drug (or within 3 months for a trial&#xD;
             with an investigational biologic).&#xD;
&#xD;
         10. Disease-related surgical intervention within 1 month prior to the first dose of study&#xD;
             drug.&#xD;
&#xD;
         11. Use of supplements that are contraindicated in the opinion of investigator, including&#xD;
             super-fortified foods and/or beverages that include coenzyme Q10, Vitamin C, Vitamin&#xD;
             E, and/or idebenone, etc, unless receiving stable doses for a minimum of 30 days prior&#xD;
             to enrollment. Changes to mitochondrial dietary supplements or their doses for 30 days&#xD;
             prior to enrollment.&#xD;
&#xD;
         12. Known hypersensitivity to ABI-009 (nab-sirolimus; ie, sirolimus and albumin), to any&#xD;
             of its excipients, or to any known rapamycin derivative or known mTOR inhibitor.&#xD;
&#xD;
         13. Patients with confirmed or suspected increased intracranial pressure, pseudotumor&#xD;
             cerebri (PTC)/idiopathic intracranial hypertension, and/or papilledema.&#xD;
&#xD;
         14. Any uncontrolled serious illness or psychiatric condition, medical condition, or other&#xD;
             medical history, including abnormal laboratory test results which, in the opinion of&#xD;
             the investigator, would be likely to interfere with the patient's participation in the&#xD;
             study, or with the interpretation of the results of the study.&#xD;
&#xD;
         15. Currently active malignancy (other than adequately treated non-melanoma skin cancers&#xD;
             [ie, squamous cell and/or basal cell carcinoma], carcinoma in situ of the cervix, or&#xD;
             other adequately treated carcinoma in situ) and/or ongoing treatment for malignancy&#xD;
             are ineligible. Patients are not considered to have a currently active malignancy if&#xD;
             they have completed therapy and are free of disease for ≥1 year.&#xD;
&#xD;
         16. Recent infection requiring systemic anti-infective treatment that was completed ≤14&#xD;
             days prior to enrollment.&#xD;
&#xD;
         17. Confirmed or suspected immunodeficiency disorder(s), including but not limited to,&#xD;
             common variable immune deficiency (CVID), complement deficiency, etc.&#xD;
&#xD;
         18. Uncontrolled diabetes mellitus, as defined by HbA1c &gt;8%, despite adequate therapy.&#xD;
&#xD;
         19. History of interstitial lung disease and/or pneumonitis, or pulmonary hypertension.&#xD;
&#xD;
         20. Use of strong inhibitors and/or inducers of cytochrome P450 (CYP) 3A4 (CYP3A4) and/or&#xD;
             p-glycoprotein (p-GP) within the 14 days prior to receiving the first dose of study&#xD;
             drug. Additionally, use of any known CYP3A4 substrates with a narrow therapeutic&#xD;
             window (eg, fentanyl, alfentanil, astemizole, cisapride, dihydroergotamine, pimozide,&#xD;
             quinidine, terfenadine) within the 14 days prior to receiving the first dose of study&#xD;
             drug. [All medications will be reviewed by the (Institutional) Investigational&#xD;
             Pharmacy to ensure that strong inducers and/or inhibitors of CYP3A4 and/or p-GP, or&#xD;
             CYP3A4 substrates with a narrow therapeutic window, have not been administered within&#xD;
             14 days prior to the first dose of study drug; patients receiving anticonvulsant&#xD;
             medications within the 14 days prior to receiving the first dose of study drug may be&#xD;
             enrolled at the discretion of the investigator].&#xD;
&#xD;
         21. Known human immunodeficiency virus (HIV), active hepatitis B or hepatitis C&#xD;
             infection(s).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Berta Grigorian</last_name>
    <phone>8184168378</phone>
    <email>bgrigorian@aadibio.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2018</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leigh Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

